Jim Birchenough
Stock Analyst at Wells Fargo
(2.66)
# 2,092
Out of 4,941 analysts
36
Total ratings
45%
Success rate
23.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $0.52 | +286.47% | 2 | Dec 31, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $56.60 | +23.67% | 3 | Feb 22, 2024 | |
| MEIP MEI Pharma | Downgrades: Equal-Weight | $260 → $40 | $4.79 | +735.07% | 4 | Mar 25, 2022 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $13.01 | +268.95% | 3 | Feb 9, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $6 → $7 | $0.08 | +9,014.58% | 2 | Sep 22, 2021 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $0.94 | +13,784.44% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $1.80 | +677.78% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $25.66 | +465.08% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $120.02 | -47.51% | 5 | Oct 29, 2020 | |
| RNA Avidity Biosciences | Initiates: Overweight | n/a | $46.23 | - | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 | $14.30 | +291.61% | 3 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $734 | $556.56 | +31.88% | 2 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $180 | $3.91 | +4,503.58% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $5.62 | +487.19% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.52
Upside: +286.47%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $56.60
Upside: +23.67%
MEI Pharma
Mar 25, 2022
Downgrades: Equal-Weight
Price Target: $260 → $40
Current: $4.79
Upside: +735.07%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $13.01
Upside: +268.95%
Adaptimmune Therapeutics
Sep 22, 2021
Maintains: Equal-Weight
Price Target: $6 → $7
Current: $0.08
Upside: +9,014.58%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $0.94
Upside: +13,784.44%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $1.80
Upside: +677.78%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $25.66
Upside: +465.08%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $120.02
Upside: -47.51%
Avidity Biosciences
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $46.23
Upside: -
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $14.30
Upside: +291.61%
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $556.56
Upside: +31.88%
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $3.91
Upside: +4,503.58%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $5.62
Upside: +487.19%